

External Infusion Pumps

Tricenturion

Contractor Information	
Contractor Name	Tricenturion
Contractor Number	77011
Contractor Type	DMERC
LCD Information	
LCD Database ID Number	L5044
LCD Version Number	17
LCD Title	External Infusion Pumps
Contractor's Determination Number	EIP20040701
AMA CPT / ADA CDT Copyright Statement	CPT codes, descriptions and other data only are copyright 2004 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. CDT-4 codes and descriptions are © 2004 American Dental Association. All rights reserved.
CMS National Coverage Policy	CMS Pub. 100-3, Chapter 1, Section 280.14
Primary Geographic Jurisdiction	CT DE MA ME NH NJ NY PA RI VT
Oversight Region	Region III
CMS Consortium	Northeast
DMERC Region LCD Covers	Region A
Original Determination Effective Date	For services performed on or after 10/01/1993
Original Determination Ending Date	
Revision Effective Date	For services performed on or after 07/02/2004
Revision Ending Date	
Indications and Limitations of Coverage and/or Medical Necessity	For any item to be covered by Medicare, it must 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, and 3) meet all other applicable Medicare statutory and regulatory requirements. For the items addressed in this medical policy, the criteria for "reasonable and necessary" are defined by the following indications and limitations of coverage and/or medical necessity.

For an item to be covered by Medicare a written signed and dated order must be received by the supplier before a claim is submitted to the DMERC. If the supplier bills for an item addressed in this policy without first receiving the completed order, the item will be denied as not medically necessary.

An external infusion pump is covered for the following indications (I-V):

I. Administration of deferoxamine for the treatment of chronic iron overload.

II. Administration of chemotherapy for the treatment of primary hepatocellular carcinoma or colorectal cancer where this disease is unresectable or where the patient refuses surgical excision of the tumor. Anticancer chemotherapy drugs used in these conditions are not required to meet the criteria described by indication V, situation A.

III. Administration of morphine when used in the treatment of intractable pain caused by cancer.

IV. Administration of continuous subcutaneous insulin for the treatment of diabetes mellitus, (ICD-9 codes 250.00-250.93), which has been documented by a fasting serum C-peptide level that is less than or equal to 110 percent of the lower limit of normal of the laboratory's measurement method, if either of the following criteria (1) or (2) are met:

1. The patient has completed a comprehensive diabetes education program, has been on a program of multiple daily injections of insulin (i.e., at least 3 injections per day), with frequent self-adjustments of insulin dose for at least 6 months prior to initiation of the insulin pump, and has documented frequency of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of the insulin pump, and meets one or more of the following criteria (a - e) while on the multiple injection regimen:

(a) Glycosylated hemoglobin level (HbA1C) greater than 7%

(b) History of recurring hypoglycemia

(c) Wide fluctuations in blood glucose before mealtime

(d) Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL

(e) History of severe glycemc excursions

2. The patient has been on an external insulin infusion pump prior to enrollment in Medicare and has documented frequency of glucose self-testing an average of at least 4 times per day during the month prior to Medicare enrollment.

For patients who have obtained an external insulin infusion pump that was not eligible for reimbursement by Medicare prior to January 1, 2002, insulin and supplies used with the pump are covered for dates of service on or after January 1, 2002 provided the patient has a fasting C-peptide such that the test result is less than or equal to 110 percent of the lower limit of normal of the laboratory's measurement method.

Continued coverage of an external insulin pump and supplies requires that the patient be seen and evaluated by the treating physician at least every 3 months. In addition, the external insulin infusion pump must be ordered and

follow-up care rendered by a physician who manages multiple patients on continuous subcutaneous insulin infusion therapy and who works closely with a team including nurses, diabetic educators, and dieticians who are knowledgeable in the use of continuous subcutaneous insulin infusion therapy.

V. Administration of other drugs if either of the following sets of criteria (1) or (2) are met:

Criteria set 1:

- Parenteral administration of the drug in the home is reasonable and necessary.
- An infusion pump is necessary to safely administer the drug.
- The drug is administered by a prolonged infusion of at least 8 hours because of proven improved clinical efficacy.
- The therapeutic regimen is proven or generally accepted to have significant advantages over intermittent bolus administration regimens or infusions lasting less than 8 hours.

Criteria set 2:

- Parenteral administration of the drug in the home is reasonable and necessary.
- An infusion pump is necessary to safely administer the drug.
- The drug is administered by intermittent infusion (each episode of infusion lasting less than 8 hours) which does not require the patient to return to the physician's office prior to the beginning of each infusion.
- Systemic toxicity or adverse effects of the drug is unavoidable without infusing it at a strictly controlled rate as indicated in the Physicians Desk Reference, or the U.S. Pharmacopeia Drug Information.

Coverage for the administration of other drugs, based on criteria set (1) or (2), using an external infusion pump is limited to the following situations (A) - (F):

A. Administration of the anticancer chemotherapy drugs cladribine, fluorouracil, cytarabine, bleomycin, floxuridine, doxorubicin (non-liposomal), vincristine or vinblastine by continuous infusion over at least 8 hours when the regimen is proven or generally accepted to have significant advantages over intermittent administration regimens.

B. Administration of narcotic analgesics (except meperidine) in place of morphine to a patient with intractable pain caused by cancer who has not responded to an adequate oral/transdermal therapeutic regimen and/or cannot tolerate oral/transdermal narcotic analgesics.

C. Administration of the following antifungal or antiviral drugs: acyclovir, foscarnet, amphotericin B, and ganciclovir. Liposomal amphotericin B preparations (J0287-J0289) are covered for patients who meet one of the following criteria:

1) The patient has suffered some significant toxicity that would preclude the use of standard amphotericin B and is unable to complete the course of therapy

without the liposomal form, or

2) The patient has significantly impaired renal function.

Payment for the liposomal form will be based on the allowance for the least costly medically appropriate alternative, standard amphotericin B (J0285), unless accompanied by a statement from the physician substantiating the medical need for the liposomal form of amphotericin B for a particular patient.

D. Administration of parenteral inotropic therapy, using the drugs dobutamine, milrinone and/or dopamine for patients with congestive heart failure and depressed cardiac function if a patient meets all of the following criteria:

1) Dyspnea at rest is present despite treatment with maximum or near maximum tolerated doses of digoxin, a loop diuretic, and an angiotensin converting enzyme inhibitor or another vasodilator (e.g., hydralazine or isosorbide dinitrate), used simultaneously (unless allergic or intolerant), and

2) Doses are within the following ranges (lower doses will be covered only if part of a weaning or tapering protocol from higher dose levels):

- a) Dobutamine - - 2.5-10 mcg/kg/min
- b) Milrinone - - 0.375-0.750 mcg/kg/min
- c) Dopamine - - less than or equal to 5 mcg/kg/min, and

3) Cardiac studies by either invasive hemodynamic technique or using thoracic electrical bioimpedance (impedance cardiography), performed within 6 months prior to the initiation of home inotropic therapy showing (a) cardiac index (CI) is less than or equal to 2.2 liters/min/meter squared and/or pulmonary capillary wedge pressure (PCWP) is greater than or equal to 20 mm Hg before inotrope infusion on maximum medical management and (b) at least a 20% increase in CI and/or at least a 20% decrease in PCWP during inotrope infusion at the dose initially prescribed for home infusion, and

4) There has been an improvement in patient well being, (less dyspnea, improved diuresis, improved renal function and/or reduction in weight) with the absence of dyspnea at rest at the time of discharge and the capability of outpatient evaluation by the prescribing physician at least monthly, and

5) In the case of continuous infusion, there is documented deterioration in clinical status when the drug(s) is tapered or discontinued under observation in the hospital, or

In the case of intermittent infusions, there is documentation of repeated hospitalizations for congestive heart failure despite maximum medical management, and

6) Any life threatening arrhythmia is controlled prior to hospital discharge and there is no need for routine electrocardiographic monitoring at home, and

7) The patient is maintained on the lowest practical dose and efforts to decrease the dose of the drug(s) or the frequency/duration of infusion are documented during the first 3 months of therapy, and

8) The patient's cardiac symptoms, vital signs, weight, lab values, and response to therapy are routinely assessed and documented in the patient's medical record.

E. Administration of parenteral epoprostenol (J1325) or subcutaneous treprostinil (Q4077) for patients with pulmonary hypertension if they meet the following disease criteria:

1) The pulmonary hypertension is not secondary to pulmonary venous hypertension (e.g., left sided atrial or ventricular disease, left sided valvular heart disease, etc.) or disorders of the respiratory system (e.g., chronic obstructive pulmonary disease, interstitial lung disease, obstructive sleep apnea or other sleep disordered breathing, alveolar hypoventilation disorders, etc.); and

2) The patient has primary pulmonary hypertension or pulmonary hypertension which is secondary to one of the following conditions: connective tissue disease, thromboembolic disease of the pulmonary arteries, human immunodeficiency virus (HIV) infection, cirrhosis, diet drugs, congenital left to right shunts, etc. If these conditions are present, the following criteria must be met:

a) The pulmonary hypertension has progressed despite maximal medical and/or surgical treatment of the identified condition; and

b) The mean pulmonary artery pressure is greater than 25 mm Hg at rest or greater than 30 mm Hg with exertion; and

c) The patient has significant symptoms from the pulmonary hypertension (i.e., severe dyspnea on exertion, and either fatigability, angina, or syncope); and

d) Treatment with oral calcium channel blocking agents has been tried and failed, or has been considered and ruled out.

F. Gallium nitrate is covered for the treatment of symptomatic cancer-related hypercalcemia (ICD-9 275.42). In general, patients with a serum calcium (corrected for albumin) less than 12 mg/dl would not be expected to be symptomatic.

The recommended usage for gallium nitrate is daily for five consecutive days. Use for more than 5 days will be denied as not medically necessary.

More than one course of treatment for the same episode of hypercalcemia will be denied as not medically necessary.

External infusion pumps and related drugs and supplies will be denied as not medically necessary when the criteria described by indication (I), (II), (III), (IV) or (V) are not met.

When an infusion pump is covered, the drug necessitating the use of the pump and necessary supplies are also covered. When a pump has been purchased by the Medicare program, other insurer, or the patient, or the rental cap has been reached, the drug necessitating the use of the pump, and supplies are covered as long as the coverage criteria for the pump are met.

Medicare only pays for one pump (K0455) for administering epoprostenol and treprostinil; the supplier is responsible for ensuring that there is an appropriate and acceptable contingency plan to address any emergency situations or mechanical failures of the equipment. A second pump provided as a backup will be denied as not medically necessary.

An external infusion pump and related drugs and supplies will be denied as not

	<p>medically necessary in the home setting for the treatment of thromboembolic disease and/or pulmonary embolism by heparin infusion.</p> <p>An infusion controller device (E1399) is not medically necessary.</p> <p>An IV pole (E0776) is covered only when a stationary infusion pump (E0791) is covered. It is considered not medically necessary if it is billed with an ambulatory infusion pump (E0779, E0780, E0781, E0784, or K0455).</p> <p>Supplies for the maintenance of a parenteral drug infusion catheter (A4221) are covered during the period of covered use of an infusion pump. They are also covered for the weeks in between covered infusion pump use, not to exceed 4 weeks per episode.</p> <p>Supplies used with an external infusion pump, A4222 or K0552, are covered during the period of covered use of an infusion pump. Allowance is based on the number of cassettes or bags (A4222) prepared or syringes (K0552) used. For intermittent infusions, no more than one cassette or bag is covered for each dose of drug. For continuous infusion, the concentration of the drug and the size of the cassette, bag, or syringe should be maximized to result in the fewest cassettes, bags, or syringes in keeping with good pharmacologic and medical practice.</p> <p>Drugs and supplies that are dispensed but not used for completely unforeseen circumstances (e.g., emergency admission to hospital, drug toxicity, etc.) are covered. Suppliers are expected to anticipate changing needs for drugs (e.g., planned hospital admissions, drug level testing with possible dosage change, etc.) in their drug and supply preparation and delivery schedule.</p> <p>Supplies used with an external insulin infusion pump are covered during the period of covered use of an infusion pump and are billed using code A4221 and K0552.</p> <p>Charges for drugs administered by a DME infusion pump may only be billed by the entity that actually dispenses the drug to the Medicare beneficiary and that entity must be permitted under all applicable federal, state, and local laws and regulations to dispense drugs. Only entities licensed in the state where they are physically located may bill the DMERC for infusion drugs. Drugs and related supplies and equipment billed by a supplier who does not meet these criteria will be denied as not medically necessary.</p>
<p>Coverage Topic</p>	<p>Durable Medical Equipment Prescription Drugs</p>
<p>Coding Information</p>	
<p>CPT/HCPCS Codes</p>	<p>The appearance of a code in this section does not necessarily indicate coverage.</p> <p>HCPCS MODIFIERS:</p> <p>EY – No physician or other licensed health care provider order for this item or service GY - Item or service statutorily excluded or does not meet the definition of any Medicare benefit. KX - Specific required documentation on file.</p>

EQUIPMENT

E0776 IV POLE

E0779 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION 8 HOURS OR GREATER

E0780 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION LESS THAN 8 HOURS

E0781 AMBULATORY INFUSION PUMP, SINGLE OR MULTIPLE CHANNELS, ELECTRIC OR BATTERY OPERATED, WITH ADMINISTRATIVE EQUIPMENT, WORN BY PATIENT

E0782 INFUSION PUMP, IMPLANTABLE, NON-PROGRAMMABLE (INCLUDES ALL COMPONENTS, E.G., PUMP, CATHETER, CONNECTORS, ETC.)

E0784 EXTERNAL AMBULATORY INFUSION PUMP, INSULIN

E0791 PARENTERAL INFUSION PUMP, STATIONARY, SINGLE OR MULTI-CHANNEL

E1399 DURABLE MEDICAL EQUIPMENT, MISCELLANEOUS

K0455 INFUSION PUMP USED FOR UNINTERRUPTED PARENTERAL ADMINISTRATION OF MEDICATION, (E.G., EPOPROSTENOL OR TREPROSTINOL)

SUPPLIES

A4221 SUPPLIES FOR MAINTENANCE OF DRUG INFUSION CATHETER, PER WEEK (LIST DRUG SEPARATELY)

A4222 SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, PER CASSETTE OR BAG (LIST DRUG SEPARATELY)

A4305 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF 50 ML OR GREATER PER HOUR

A4306 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF 5 ML OR LESS PER HOUR

A9270 NON-COVERED ITEM OR SERVICE

K0552 SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, SYRINGE TYPE CARTRIDGE, STERILE, EACH

K0601 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 1.5 VOLT, EACH

K0602 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 3 VOLT, EACH

K0603 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, ALKALINE, 1.5 VOLT, EACH

K0604 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 3.6 VOLT, EACH

K0605 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 4.5 VOLT, EACH

DRUGS

J0285 INJECTION, AMPHOTERICIN B, 50 MG

J0287	INJECTION, AMPHOTERICIN B LIPID COMPLEX, 10 MG
J0288	INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX, 10 MG
J0289	INJECTION, AMPHOTERICIN B LIPOSOME, 10 MG
J0895	INJECTION, DEFEROXAMINE MESYLATE, 500 MG
J1170	INJECTION, HYDROMORPHONE, UP TO 4 MG
J1250	INJECTION, DOBUTAMINE HYDROCHLORIDE, PER 250 MG
J1325	INJECTION, EPOPROSTENOL, 0.5 MG
J1455	INJECTION, FOSCARNET SODIUM, PER 1000 MG
J1570	INJECTION, GANCICLOVIR SODIUM, 500 MG
J1817	INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS
J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG
J2260	INJECTION, MILRINONE LACTATE, 5 MG
J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG
J2271	INJECTION, MORPHINE SULFATE, 100MG
J2275	INJECTION, MORPHINE SULFATE (PRESERVATIVE-FREE STERILE SOLUTION), PER 10 MG
J3010	INJECTION, FENTANYL CITRATE, 0.1 MG
J7799	NOC DRUGS, OTHER THAN INHALATION DRUGS, ADMINISTERED THROUGH DME
J9000	DOXORUBICIN HCL, 10 MG
J9040	BLEOMYCIN SULFATE, 15 UNITS
J9065	INJECTION, CLADRIBINE, PER 1 MG
J9100	CYTARABINE, 100 MG
J9110	CYTARABINE, 500 MG
J9190	FLUOROURACIL, 500 MG
J9200	FLOXURIDINE, 500 MG
J9360	VINBLASTINE SULFATE, 1 MG
J9370	VINCRISTINE SULFATE, 1 MG
J9375	VINCRISTINE SULFATE, 2 MG
J9380	VINCRISTINE SULFATE, 5 MG
Q4075	INJECTION, ACYCLOVIR, 5 MG
Q4076	INJECTION, DOPAMINE HCL, 40 MG
Q4077	INJECTION, TREPROSTINIL, 1 MG

Does the CPT 30% Coding Rule Apply?	No
ICD-9 Codes that Support Medical Necessity	<p>The presence of an ICD-9 code listed in this section is not sufficient by itself to assure coverage. Refer to the section on "Indications and Limitations of Coverage and/or Medical Necessity" for other coverage criteria and payment information.</p> <p>For HCPCS codes E0784, J1817</p> <p>250.00 - 250.93</p>
Diagnoses that Support Medical Necessity	<p>For the specific HCPCS codes indicated above, refer to the previous section.</p> <p>For all other HCPCS codes, diagnoses are not specified.</p>
ICD-9 Codes that DO NOT Support Medical Necessity	<p>For the specific HCPCS codes indicated above, all ICD-9 codes that are not specified in the previous section.</p> <p>For all other HCPCS codes, diagnoses are not specified.</p>
Non-Medical Necessity ICD-9 Codes Asterisk Explanation	
Diagnoses that DO NOT Support Medical Necessity	<p>For the specific HCPCS codes indicated above, all diagnoses that are not specified in the previous section.</p> <p>For all other HCPCS codes, diagnoses are not specified.</p>
General Information	
Documentation Requirements	<p>Section 1833(e) of the Social Security Act precludes payment to any provider of services unless "there has been furnished such information as may be necessary in order to determine the amounts due such provider" (42 U.S.C. section 13951(e)). It is expected that the patient's medical records will reflect the need for the care provided. The patient's medical records include the physician's office records, hospital records, nursing home records, home health agency records, records from other healthcare professionals and test reports. This documentation must be available to the DMERC upon request.</p> <p>An order for each item billed must be signed and dated by the treating physician, kept on file by the supplier, and made available to the DMERC upon request. Items billed to the DMERC before a signed and dated order has been received by the supplier must be submitted with an EY modifier added to each affected HCPCS code.</p> <p>A Certificate of Medical Necessity (CMN) which has been completed, signed, and dated by the treating physician must be kept on file by the supplier and made available to the DMERC on request. The CMN may act as a substitute for a written order if it contains all of the required elements of an order. The CMN for External Infusion Pumps is HCFA Form 851. The initial claim must include a</p>

	<p>copy of the CMN.</p> <p>For external insulin infusion pumps, an ICD-9 diagnosis code (specific to the 5th digit), describing the condition which necessitates the pump, must be included on each order and CMN for the pump, insulin and/or supplies.</p> <p>If a patient begins using an infusion for one drug and subsequently the drug is changed or another drug is added, a revised CMN must be submitted for use of the pump with the new or additional drug. In the case of an additional drug, all drugs for which the pump is used should be included on the revised CMN. For all claims for external insulin infusion pumps, insulin, and/or supplies, if the results of the patient's C-peptide level meet the requirements outlined in section IV of the Coverage and Payment Rules, a KX modifier should be added to the HCPCS code.</p> <p>If an inotropic drug is ordered, the initial claim must include a copy of the order (prescription and documentation from the treating physician) which includes information relating to each of the criteria (D1-D8) defined in the Coverage and Payment Rules section. This must include the before and after inotropic drug infusion values defined in D3. A suggested form for collecting this information is attached.</p> <p>Questions pertaining to medical necessity on any form used to collect this information may not be completed by the supplier or by anyone in a financial relationship with the supplier. If coverage criteria stated in the policy are not met, the claim should be accompanied by a copy of a letter from the physician giving details of the patient's history (e.g., dates of past hospitalization for heart failure, prior use of parenteral inotropic and the results, etc.). If invasive hemodynamic studies or impedance cardiography were not performed, the claim should be accompanied by a letter from the attending physician explaining the rationale for not performing the tests and accompanied by any other documentation deemed appropriate to explain this exception.</p> <p>If epoprostenol or treprostinil is ordered, the initial claim must include signed and dated information from the treating physician stating the patient's diagnosis, the patient's current symptoms caused by pulmonary hypertension, and date and results of the pulmonary artery pressure. There must be a statement that the pulmonary hypertension is not secondary to pulmonary venous hypertension or a disorder of the respiratory system. There must be a statement of whether oral calcium channel blocking agents were tried and if so, the results, and if not, why a trial was not conducted.</p> <p>If the liposomal form of amphotericin B is ordered, the initial claim for J0287, J0288, or J0289 must be submitted with a statement from the physician indicating why the liposomal form of amphotericin B is needed for a particular patient.</p> <p>Refer to the Supplier Manual for more information on documentation requirements.</p>
Appendices	
Utilization Guidelines	Refer to Indications and Limitations of Coverage and/or Medical Necessity.
Sources of Information and Basis for Decision	Reserved for future use.
Advisory Committee Meeting Notes	This policy does not reflect the sole opinion of the contractor or contractor medical director. Although the final decision rests with the contractor, this policy was developed in cooperation with advisory groups, which includes representatives from relevant clinical groups and the supplier community.

Start Date of Comment Period	04/16/1993
End Date of Comment Period	05/31/1993
Start Date of Notice Period	08/01/1993
Revision History Number	EIP016
Revision History Explanation	<p>Revision effective date: 7/01/2004 LMRP Converted to LCD and Policy Article INDICATIONS AND LIMITATIONS OF COVERAGE: Added gallium nitrate to list of covered drugs (F) for cancer related hypercalcemia</p> <p>Revision effective date: 10/01/2003 HCPCS CODES AND MODIFIERS: Added: Q4075, Q4076, Q4077 Discontinued: J0286 CODING GUIDELINES: Removed instructions for treprostinil</p> <p>Revision effective date: 04/01/2003 HCPCS CODES AND MODIFIERS: Added: EY modifier , J0287, J0288, J0289, J1817, K0552, K0601, K0602, K0603, K0604, K0605 Discontinued: A4232, A4632, J1820, K0548 Revised: K0455 INDICATIONS AND LIMITATIONS OF COVERAGE: Added treprostinil to list of covered drugs for pulmonary hypertension. . Adds standard language concerning coverage of items without an order. CODING GUIDELINES: Adds instructions for treprostinil. Clarifies coding of A4222. Adds guidelines for K0552. DOCUMENTATION REQUIREMENTS: Adds standard language concerning use of EY modifier for items without an order</p> <p>The revision dates listed below are the dates the revisions were published and not necessarily the effective dates for the revisions.</p> <p>04/01/2002 - C-peptide level minimum raised to less than or equal to 110% of lower limit of normal of laboratory's measurement method. HCPCS code K0548 added for insulin lispro. Expanded allowable dosage range for dopamine (less than or equal to 5 mcg/kg/min). Replaced ZX with KX modifier.</p> <p>12/01/2000 – Incorporated allowance for the use of either invasive hemodynamic monitoring or thoracic electrical bioimpedance, also known as impedance cardiography, in order to qualify a patient for Medicare coverage of inotropic drugs in the treatment of congestive heart failure.</p> <p>10/01/2000 - Revised coverage criteria for epoprostenol (Flolan®), effective for claims with dates of service on or after October 1, 2000.</p> <p>04/01/2000 – Incorporated new HCPCS codes that became effective January 1, 2000. In addition, the coverage criteria for liposomal amphotericin B were corrected to consider coverage in patients with impaired renal function rather than impaired hepatic function. Included new coverage criteria for external insulin infusion pumps (HCPCS code E0784) as a result of a revised national</p>

coverage determination for section 60-14 of the Coverage Issues Manual. As outlined in the LMRP, external insulin infusion pumps and supplies are covered for type 1 diabetics (only) who meet Medicare coverage criteria. An ICD-9-CM code specific to the fifth digit (e.g., 250.11), describing the condition which necessitates the insulin pump, must be included on all claims for insulin pumps, insulin and/or supplies. Submission of a claim lacking a covered ICD-9-CM diagnosis code will result in a denial for medical necessity. Alternatively, failure to provide an ICD-9-CM diagnosis code on the claim will result in rejection of the claim for missing information. Supplies for the insulin pump should be billed using codes A4221 and A4232. Insulin for use in the pump is billed using code J1820. Codes A4230 (infusion set for external insulin pump, non-needle cannula type) and A4231 (infusion set for external insulin pump, needle type) are not valid for claim submission to the DMERC because they are included in code A4221.

09/01/1999 – Typo corrected from digitoxin to digoxin.

06/01/1999 – Added HCPCS codes (J0285 crosswalk from K0453, J0286, J2271). General "Reasonable and Necessary" criteria were added to the beginning of the "Coverage and Payment Rules" section. The first part of "Coverage and Payment Rules" was reformatted to improve readability. Changes in the numbering scheme and the addition of bullets and references in the text are intended to improve clarity and interpretation of eligibility criteria. Coverage of liposomal amphotericin B (J0286) was added. This code became effective January 1, 1999, and is covered for patients who have had significant toxicity to standard amphotericin and are unable to complete that course of therapy or for those patients who have significantly impaired hepatic function. An indication for use of epoprostenol (Flolan®)(Code J1325) was added. Effective for dates of service on or after February 1, 1999, J1325 will be covered for those patients with pulmonary hypertension secondary to a connective tissue disease.

03/01/1998 – Crosswalked HCPCS codes K0110 and K0111 to A4221 and A4222. Added HCPCS code K0455. Code J9010 crosswalked to J9000. Added criteria E in Coverage and Payment Rules section regarding parenteral epoprostenol. Added language regarding entities licensed to dispense drugs.

12/01/1997 – Clerical correction.

10/01/1996 – Removed HCPCS J3370 and XX009. Removed vancomycin (not covered effective 9/1/96) in criteria C in Coverage and Payment Rules section. Removed Related Clinical Information section. Added effective date for code J1250 in Coding Guidelines section.

04/01/1996 – Added code K0417. Added effective dates for codes K0417, XX009, and J1250 in Coding Guidelines section.

01/01/1996 – Added codes A9270, J1250, J1455, J1570, J2175, J2260, J3010, J9010, J9110, J9375, & J9380. Added definition for code K0284. Revised Coverage and Payment Rules section. Added Related Clinical Information section. Revised Coding Guidelines and Documentation section.

10/01/1995 – Added codes K0284, J2275 & J9065.

12/01/1993 – Revised description for J1170. Added code J3370 & XX009.

This LCD was converted from an LMRP on 4/28/2004

Notes	
Does this LCD contain a "Least Costly Alternative" provision?	Yes
Related Documents	Article(s) A19713 - External Infusion Pumps - Policy Article - Effective July, 2004
LCD Attachments	EIP CMN 851 (57,863 bytes) Home Parenteral Inotropic Therapy: Data Collection Form (6,128 bytes)

External Infusion Pumps - Policy Article - Effective July, 2004

Tricenturion

Contractor Information	
Contractor Name	Tricenturion
Contractor Number	77011
Contractor Type	DMERC
Article Information	
Article Database ID Number	A19713
Article Type	Detailed Article
Article Version Number	3
Article Title	External Infusion Pumps - Policy Article - Effective July, 2004
Is the AMA CPT / ADA CDT Copyright Statement Required?	Yes CPT codes, descriptions and other data only are copyright 2004 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. CDT-4 codes and descriptions are © 2004 American Dental Association. All rights reserved.
Primary Geographic Jurisdiction	CT DE MA ME NH NJ NY PA RI VT
DMERC Region Article Covers	Region A
Article Publication Date	06/01/2004
Article Beginning Effective Date	07/01/2004
Article Ending Effective Date	
Article Text	<p>NON-MEDICAL NECESSITY COVERAGE AND PAYMENT RULES</p> <p>Injectable drugs administered in a physician's office, whether with or without a pump, must be billed to the local carrier and not the DMERC. Drugs put into an infusion pump in the physician's office for use in the patient's home must be billed to the DMERC if the pump is billed to the DMERC.</p> <p>Disposable drug delivery systems, including elastomeric infusion pumps (A4305, A4306) are non-covered devices because they do not meet the Medicare definition of durable medical equipment. Drugs and supplies used with disposable drug</p>

delivery systems are also non-covered items.

Catheter insertion devices for use with external insulin infusion pump infusion cannulas are included in the allowance for code A4221 and are not separately payable.

The DMERC does not process claims for implantable infusion pumps (J0782, J0783, J0785, J0786) or drugs and supplies used in conjunction with an implantable infusion pump. Claims for these items must be submitted to the local carrier

CODING GUIDELINES

An ambulatory infusion pump (E0781) is an electrical or battery operated device which is used to deliver solutions containing a parenteral drug under pressure at a regulated flow rate. It is small, portable, and designed to be carried by the patient.

A stationary infusion pump (E0791) is an electrical device which serves the same purpose as an ambulatory pump but is larger and typically mounted on a pole.

A disposable drug delivery system (A4305, A4306) is a device used to deliver solutions containing parenteral drugs under pressure generated from the elastic properties of the container. It is commonly called an elastomeric infusion pump.

An infusion controller (E1399) is an electrical device which regulates the flow of parenteral solutions under gravity pressure.

A reusable mechanical infusion pump (E0779) is a device used to deliver solutions containing parenteral drugs under pressure at a constant flow rate determined by the tubing with which it is used. It is small, portable, and designed to be carried by the patient. It must be capable of a single infusion cycle of at least 8 hours.

Code E0780 describes a mechanical infusion pump which is similar to an E0779 pump, but which is only capable of a single infusion cycle of less than 8 hours.

Code K0455 describes an ambulatory electrical infusion pump which is used for the administration of epoprostenol.

Code A4221 includes dressings for the catheter site and flush solutions not directly related to drug infusion. The catheter site may be a peripheral intravenous line, a peripherally inserted central catheter (PICC), a centrally inserted intravenous line with either an external or a subcutaneous port, or an epidural catheter. Code A4221 also includes all cannulas, needles, dressings and infusion supplies (excluding the insulin reservoir) related to continuous subcutaneous insulin infusion via external insulin infusion pump (E0784). Billing for more than 1 unit of service per week is incorrect use of the code and will be denied accordingly.

Code A4222 includes the cassette or bag, diluting solutions, tubing and other administration supplies, port cap changes, compounding charges, and preparation charges. This code is not used for a syringe-type reservoir.

Code K0552 describes a syringe-type reservoir that is used with the external insulin infusion pump (E0784) or with a K0455 pump when it is used to administer treprostinil. The reservoir may be either glass or plastic and includes the needle for drawing up the drug. This code does not include the drug for use in the reservoir.

All supplies (including dressings) used in conjunction with a durable infusion pump (E0779, E0780, E0781, E0784, E0791, K0455) are billed with (1) codes A4221 and A4222 or (2) codes A4221 and K0552. Other codes should not be used for the

separate billing of these supplies. Codes A4230 (infusion set for external insulin pump, non needle cannulas type) and A4231 (infusion set for external insulin pump, needle type) are not valid for claim submission to the DMERC because they are included in code A4221.

Drugs used in a durable infusion pump must be coded using the appropriate HCPCS codes. If the drug does not have a distinct code, then use the unclassified drug code J7799. Do not use code J9999 - this code is not valid for claims billed to the DMERC.

An infusion drug not administered using a durable infusion pump must be billed using the appropriate HCPCS code plus the GY modifier. If the drug does not have a unique code, use the unclassified drug code, J3490.

Use code J2275 only for morphine sulfate that is labeled "preservative free." Morphine sulfate that is not labeled "preservative free" must be coded J2270 or J2271.

Use code J1817 for insulin administered through an external insulin pump (E0784).

For disposable drug delivery systems (e.g., elastomeric) with a flow rate of more than 5 ml per hour and less than 50 ml per hour, use code A9270.

Use code J7799 (NOC drugs, other than inhalation drugs, administered through DME) for gallium nitrate One unit of service = 500mg.

Suppliers should contact the Statistical Analysis Durable Medical Equipment Regional Carrier (SADMERC) for guidance on the correct coding of these items.

CMS Pub. 100-3, Chapter 1, Section 280.14

Coverage Topic

Durable Medical Equipment
 Prescription Drugs

Coding Information

CPT/HCPCS Codes

The appearance of a code in this section does not necessarily indicate coverage.

HCPCS MODIFIERS:

EY – No physician or other health care provider order for this item or service
 GY - Item or service statutorily excluded or does not meet the definition of any Medicare benefit.
 KX - Specific required documentation on file.

EQUIPMENT

E0776 IV POLE

E0779 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION 8 HOURS OR GREATER

E0780 AMBULATORY INFUSION PUMP, MECHANICAL, REUSABLE, FOR INFUSION LESS THAN 8 HOURS

E0781 AMBULATORY INFUSION PUMP, SINGLE OR MULTIPLE CHANNELS, ELECTRIC OR BATTERY OPERATED, WITH ADMINISTRATIVE EQUIPMENT, WORN BY PATIENT

E0782 INFUSION PUMP, IMPLANTABLE, NON-PROGRAMMABLE (INCLUDES ALL COMPONENTS, E.G., PUMP, CATHETER, CONNECTORS, ETC.)

E0784 EXTERNAL AMBULATORY INFUSION PUMP, INSULIN

E0791 PARENTERAL INFUSION PUMP, STATIONARY, SINGLE OR MULTI-CHANNEL

E1399 DURABLE MEDICAL EQUIPMENT, MISCELLANEOUS

K0455 INFUSION PUMP USED FOR UNINTERRUPTED PARENTERAL ADMINISTRATION OF MEDICATION, (E.G., EPOPROSTENOL OR TREPROSTINOL)

SUPPLIES

A4221 SUPPLIES FOR MAINTENANCE OF DRUG INFUSION CATHETER, PER WEEK (LIST DRUG SEPARATELY)

A4222 SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, PER CASSETTE OR BAG (LIST DRUG SEPARATELY)

A4305 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF 50 ML OR GREATER PER HOUR

A4306 DISPOSABLE DRUG DELIVERY SYSTEM, FLOW RATE OF 5 ML OR LESS PER HOUR

A9270 NON-COVERED ITEM OR SERVICE

K0552 SUPPLIES FOR EXTERNAL DRUG INFUSION PUMP, SYRINGE TYPE CARTRIDGE, STERILE, EACH

K0601 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 1.5 VOLT, EACH

K0602 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, SILVER OXIDE, 3 VOLT, EACH

K0603 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, ALKALINE, 1.5 VOLT, EACH

K0604 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 3.6 VOLT, EACH

K0605 REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP OWNED BY PATIENT, LITHIUM, 4.5 VOLT, EACH

DRUGS

J0285 INJECTION, AMPHOTERICIN B, 50 MG

J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX, 10 MG

J0288 INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX, 10 MG

J0289 INJECTION, AMPHOTERICIN B LIPOSOME, 10 MG

J0895 INJECTION, DEFEROXAMINE MESYLATE, 500 MG

J1170 INJECTION, HYDROMORPHONE, UP TO 4 MG

J1250	INJECTION, DOBUTAMINE HYDROCHLORIDE, PER 250 MG
J1325	INJECTION, EPOPROSTENOL, 0.5 MG
J1455	INJECTION, FOSCARNET SODIUM, PER 1000 MG
J1570	INJECTION, GANCICLOVIR SODIUM, 500 MG
J1817	INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS
J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG
J2260	INJECTION, MILRINONE LACTATE, 5 MG
J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG
J2271	INJECTION, MORPHINE SULFATE, 100MG
J2275	INJECTION, MORPHINE SULFATE (PRESERVATIVE-FREE STERILE SOLUTION), PER 10 MG
J3010	INJECTION, FENTANYL CITRATE, 0.1 MG
J7799	NOC DRUGS, OTHER THAN INHALATION DRUGS, ADMINISTERED THROUGH DME
J9000	DOXORUBICIN HCL, 10 MG
J9040	BLEOMYCIN SULFATE, 15 UNITS
J9065	INJECTION, CLADRIBINE, PER 1 MG
J9100	CYTARABINE, 100 MG
J9110	CYTARABINE, 500 MG
J9190	FLUOROURACIL, 500 MG
J9200	FLOXURIDINE, 500 MG
J9360	VINBLASTINE SULFATE, 1 MG
J9370	VINCRISTINE SULFATE, 1 MG
J9375	VINCRISTINE SULFATE, 2 MG
J9380	VINCRISTINE SULFATE, 5 MG
Q4075	INJECTION, ACYCLOVIR, 5 MG
Q4076	INJECTION, DOPAMINE HCL, 40 MG
Q4077	INJECTION, TREPROSTINIL, 1 MG

Coding Table Information						
CPT/HCPCS Codes - Table Format	Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Comments
Bill Type Codes - Table Format	Code	Descriptor Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Comments
Revenue Codes - Table Format	Code	Descriptor Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Comments
Other Information						
Detailed Article URL						
Other Comments	Revision History Revision Effective Date: 07/01/2004 LMRP Converted to LCD and Policy Article					
Does this Article contain a "Least Costly Alternative" provision?	Yes					
Approval Notes						
Related Documents	LCD(s) L5044 - External Infusion Pumps					
Article Attachments	There are no attachments for this Article					